140 related articles for article (PubMed ID: 28784233)
1. Cutaneous Infiltration due to Waldenström Macroglobulinemia.
Oscoz-Jaime S; Agulló-Pérez AD; Llanos-Chavarri C; Yanguas-Bayona JI
Actas Dermosifiliogr (Engl Ed); 2018; 109(1):75-78. PubMed ID: 28784233
[No Abstract] [Full Text] [Related]
2. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
Tedeschi A; Picardi P; Ferrero S; Benevolo G; Margiotta Casaluci G; Varettoni M; Baratè C; Motta M; Gini G; Goldaniga MC; Visco C; Zaja F; Belsito Petrizi V; Ravelli E; Gentile M; Urbano MA; Franceschetti S; Ghione P; Orsucci L; Frustaci AM; Gaidano G; Vitolo U; Morra E
Leuk Lymphoma; 2015; 56(9):2637-42. PubMed ID: 25651423
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Laribi K; Poulain S; Willems L; Merabet F; Le Calloch R; Eveillard JR; Herbaux C; Roos-Weil D; Chaoui D; Roussel X; Tricot S; Dupuis J; Dartigeas C; Bareau B; Bene MC; Baugier de Materre A; Leblond V
Br J Haematol; 2019 Jul; 186(1):146-149. PubMed ID: 30548257
[No Abstract] [Full Text] [Related]
5. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
Laribi K; Poulain S; Willems L; Merabet F; Herbaux C; Roos-Weil D; Laribi de Materre I; Roussel X; Nudel M; Tricot S; Dupuis J; Le Calloch R; Bareau B; Leblond V
Br J Haematol; 2024 Jun; 204(6):2233-2236. PubMed ID: 38504454
[TBL] [Abstract][Full Text] [Related]
7. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
[TBL] [Abstract][Full Text] [Related]
8. Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy.
Barakat FH; Medeiros LJ; Wei EX; Konoplev S; Lin P; Jorgensen JL
Am J Clin Pathol; 2011 Mar; 135(3):365-73. PubMed ID: 21350089
[TBL] [Abstract][Full Text] [Related]
9. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
Buske C
Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
[TBL] [Abstract][Full Text] [Related]
10. A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission.
Sekiguchi Y; Wakabayashi M; Takizawa H; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
J Clin Exp Hematop; 2017 Oct; 57(2):79-81. PubMed ID: 28883220
[No Abstract] [Full Text] [Related]
11. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E; Gavriatopoulou M; Kyrtsonis MC; Roussou M; Hadjiharissi E; Symeonidis A; Repoussis P; Michalis E; Delimpasi S; Tsatalas K; Tsirigotis P; Vassou A; Vervessou E; Katodritou E; Gika D; Terpos E; Dimopoulos MA
Blood; 2015 Sep; 126(11):1392-4. PubMed ID: 26359434
[No Abstract] [Full Text] [Related]
13. Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Chien HC; Morreall D; Patil V; Rasmussen KM; Yong CM; Li CY; Passey DG; Burningham Z; Sauer BC; Halwani AS
Am J Hematol; 2021 Jun; 96(6):E184-E187. PubMed ID: 33606890
[No Abstract] [Full Text] [Related]
14. Waldenström's macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125.
Eulitt P; Fabian D; Kelly C; Hemminger J; William BM
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):54-59. PubMed ID: 28390215
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
Treon SP; Hanzis C; Tripsas C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):133-5. PubMed ID: 21454214
[TBL] [Abstract][Full Text] [Related]
16. A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia.
Ma W; Zhao J; Zhang L
Turk J Haematol; 2021 Feb; 38(1):87-89. PubMed ID: 33121225
[No Abstract] [Full Text] [Related]
17. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
18. Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine.
Diez-Feijóo R; Rodríguez-Sevilla JJ; Fernández-Rodríguez C; Flores S; Raya C; Ferrer A; Colomo L; Salar A
Front Immunol; 2021; 12():798251. PubMed ID: 35082788
[TBL] [Abstract][Full Text] [Related]
19. Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature.
Gomez A; Hoffman JE
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):e101-8. PubMed ID: 27245314
[No Abstract] [Full Text] [Related]
20. Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Carulli G; Ciancia EM; Azzarà A; Ottaviano V; Grassi S; Ciabatti E; Ferreri MI; Rocco M; Marini A; Petrini M
J Clin Exp Hematop; 2013; 53(1):29-36. PubMed ID: 23801131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
